Friday, 16 November 2018

Medtronic starts Onyx ONE Clear study in Japan and US

14 September 2018 | News

The Onyx ONE Clear study will assess the use of one-month dual antiplatelet therapy (DAPT) in US and Japanese patients who are at high risk of bleeding.

Image credit- youtube.com

Image credit- youtube.com

Medtronic has initiated a new clinical study in patients implanted with its Resolute Onyx drug-eluting stent (DES) during percutaneous coronary intervention (PCI) procedures.

The Onyx ONE Clear study will assess the use of one-month dual antiplatelet therapy (DAPT) in US and Japanese patients who are at high risk of bleeding.

DAPT is a combination of aspirin and an anti-clotting drug. The study will evaluate its safety, such as any potential cardiac risks, when used with a next-generation DES.

This study is part of the Medtronic Onyx ONE Month DAPT Programme, which also included a prior Onyx ONE Global Study. The DAPT programme is designed to recruit a total of about 2,700 patients across 140 clinical sites globally.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Survey Box

Are New-Age Healthcare Consumers In Asia Embracing Technology?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls